Exenatide
Indication
Type 2 diabetes (NICE NG28)
Green
Brand:
Bydureon®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
NICE TA248 replaced by NICE NG28
The LSCMMG recommends Bydureon® as a 1st line GLP‑1 agonist.
Recommendation
LSCMMG Recommendation:
Green
Reason for decision:
Suitable for initiation in primary care
Supporting documents: